We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · May 15, 2021

Erenumab for Episodic Migraine When Two to Four Preventive Therapies Not Useful

Journal of Neurology, Neurosurgery, and Psychiatry

 

Additional Info

Journal of Neurology, Neurosurgery, and Psychiatry
Effect of Erenumab on Functional Outcomes in Patients With Episodic Migraine in Whom 2–4 Preventives Were Not Useful: Results From the LIBERTY Study
J. Neurol. Neurosurg. Psychiatr. 2021 May 01;92(5)466-472, M Lanteri-Minet, PJ Goadsby, U Reuter, S Wen, P Hours-Zesiger, MD Ferrari, J Klatt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading